Structure and Specificity of a Human Valacyclovir Activating Enzyme:  A Homology Model of BPHL

• Published in: Molecular pharmaceutics 2004-11, Vol.1 (6), p.434-446
• Main Authors: Kim, Insook, Crippen, Gordon M, Amidon, Gordon L
• Format: Article
• Language: English
• Subjects: Acyclovir - analogs & derivatives; Acyclovir - metabolism; Amino Acid Sequence; Carboxylic Ester Hydrolases - chemistry; Carboxylic Ester Hydrolases - drug effects; Humans; Ligands; Models, Molecular; Molecular Sequence Data; Molecular Structure; Prodrugs - chemistry; Prodrugs - pharmacology; Protein Structure, Secondary; Sensitivity and Specificity; Sequence Alignment; Structure-Activity Relationship; Valine - analogs & derivatives; Valine - metabolism
• ISSN: 1543-8384; 1543-8392
• DOI: 10.1021/mp049959+

Biphenyl hydrolase-like (BPHL) protein is a novel serine hydrolase which has been identified as human valacyclovirase (VACVase), catalyzing the hydrolytic activation of valine ester prodrugs of the antiviral drugs acyclovir and ganciclovir as well as other amino acid ester prodrugs of therapeutic nucleoside analogues. The broad specificity for nucleoside analogues as parent drugs suggests that BPHL may be particularly useful as a molecular target for prodrug activation. In order to develop an initial structural view of the specificity of BPHL, a homology model of BPHL based on the crystal structure of 2-hydroxy-6-oxo-7-methylocta-2,4-dienoate hydrolase was developed using the Molecular Operating Environment package (Chemical Computing Group, Montreal, Quebec), evaluated for its stereochemical quality and identification of free cysteines, and used in a molecular docking study. The BPHL model has residues S122, H255, and D227 comprising the putative catalytic triad in proximity and potential charge−charge interaction sites, M52 or D123 for the α-amino group. The model also suggested that the structural preference of BPHL for hydrophobic amino acyl promoieties and its limited activity for the secondary alcohol substrates may be attributed to the hydrophobic acyl-binding site formed by residues I158, G161, I162, and L229, and the spatial constraint around the catalytic site by a loop on one side, the active serine and histidine on the other side, and L53 and L179 on top. In addition, the broad specificity for nucleoside analogues may be due to the relatively less constrained nucleoside-binding site opening toward the entrance of the substrate-binding pocket. The homology model of BPHL provides a basis for further investigation of the catalytic and active site residues, can account for the observed structure activity profile of BPHL, and will be useful in the design of nucleoside prodrugs. Keywords: Homology model; human valacyclovirase, biphenyl hydrolase-like; BPHL; prodrugs; α/β-hydrolase fold; substrate specificity; hydrolysis; prodrug activation; nucleoside analogue; antiviral; anticancer; drug delivery; prodrug design